VIRAGEN EUROPE LTD
10-Q, EX-11, 2000-11-14
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: VIRAGEN EUROPE LTD, 10-Q, 2000-11-14
Next: VIRAGEN EUROPE LTD, 10-Q, EX-27, 2000-11-14



<PAGE>   1


                                                                      EXHIBIT 11

                     VIRAGEN (EUROPE) LTD. AND SUBSIDIARIES
                        COMPUTATION OF PER SHARE EARNINGS

                                   (UNAUDITED)
<TABLE>
<CAPTION>

                                                                  THREE MONTHS ENDED
                                                                     SEPTEMBER 30,
                                                         ------------------------------------
                                                              2000                  1999
                                                         --------------          ------------
<S>                                                          <C>                   <C>
Basic and diluted weighted average common shares             19,715,625            16,067,153
                                                         ==============          ============
Net Loss                                                 $   (1,506,182)         $ (1,419,541)
                                                         ==============          ============
Basic and diluted loss per common share                  $        (0.08)         $      (0.09)
                                                         ==============          ============

</TABLE>






© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission